Premium
Synthesis, antimalarial activity in vitro , and docking studies of novel neolignan derivatives
Author(s) -
Pereira Glaécia A. N.,
Souza Gisele C.,
Santos Lourivaldo S.,
Barata Lauro E. S.,
Meneses Carla C. F.,
Krettli Antoniana U.,
DanielRibeiro Cláudio Tadeu,
Alves Cláudio Nahum
Publication year - 2017
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12968
Subject(s) - plasmodium falciparum , docking (animal) , chloroquine , in vitro , cysteine protease , chemistry , in silico , biology , malaria , virology , pharmacology , stereochemistry , biochemistry , protease , enzyme , medicine , immunology , gene , nursing
The absence of effective vaccines against malaria and the difficulties associated with controlling mosquito vectors have left chemotherapy as the primary control measure against malaria. However, the emergence and spread of parasite resistance to conventional antimalarial drugs result in a worrisome scenario making the search for new drugs a priority. In the present study, the activities of nine neolignan derivatives were evaluated as follows: (i) against blood forms of chloroquine‐resistant Plasmodium falciparum (clone W2), using the tritiated hypoxanthine incorporation and anti‐ HRPII assays; (ii) for cytotoxic activity against cultured human hepatoma cells (HepG2); and (iii) for intermolecular interaction with the P. falciparum cysteine protease of falcipain‐2 (F2) by molecular docking. The neolignan derivatives 9 and 10 showed activity against the blood form of the chloroquine‐resistant P. falciparum clone W2 and were not cytotoxic against cultured human hepatoma cells. A molecular docking study of these two neolignans with FP 2 revealed several intermolecular interactions that should guide the design of future analogs.